Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several claims are either unsupported or conflict with the provided label excerpt. Many statements about systemic atropine use, organophosphate poisoning, administration routes, and non-ophthalmic indications are not supported by the provided labeling for atropine sulfate ophthalmic solution 1%.
Category Scores
Accurate Statements
Atropine is a competitive antagonist of muscarinic acetylcholine receptors.
Mechanism of Action: Atropine is a reversible antagonist of muscarine-like actions of acetyl-choline; antimuscarinic agent.
By blocking these receptors, atropine inhibits the effects of the parasympathetic nervous system.
Systemic adverse events described as related to its anti-muscarinic activity (anti-muscarinic effect).
Blocking muscarinic acetylcholine receptors increases heart rate.
Systemic adverse events include tachycardia.
Blocking muscarinic acetylcholine receptors decreases salivation.
Systemic adverse events include dryness of skin, mouth and throat from decreased secretions from mucus membranes.
Blocking muscarinic acetylcholine receptors decreases bronchial secretions.
Systemic adverse events include dryness of skin, mouth and throat from decreased secretions from mucus membranes.
Blocking muscarinic acetylcholine receptors causes pupil dilation.
Clinical Pharmacology: topical atropine results in unopposed sympathetic dilator activity and mydriasis.
Blocking muscarinic acetylcholine receptors relaxes smooth muscles in the gastrointestinal and urinary tracts.
No explicit GI/urinary smooth muscle statement in provided excerpt.
Atropine has anticholinergic side effects.
Adverse reactions described as systemic effects related to anti-muscarinic activity; also ocular reactions such as photophobia/blurred vision.
Atropine can cause confusion.
Systemic adverse events reported include restlessness, irritability or delirium from CNS stimulation.
Atropine can cause delirium.
Systemic adverse events reported include restlessness, irritability or delirium.
Atropine can exacerbate glaucoma.
Not explicitly stated in provided excerpt.
Atropine is available as eye drops for ophthalmic use.
Dosage forms and strengths: Ophthalmic Solution: 1% atropine sulfate, USP.
Unsupported Statements
Atropine is used to treat bradycardia by increasing heart rate.
Provided labeling excerpt is for atropine sulfate ophthalmic solution 1% and does not describe bradycardia treatment.
Atropine is used to counteract organophosphate poisoning by blocking the effects of acetylcholine on the parasympathetic nervous system.
No organophosphate poisoning indication is present in provided labeling excerpt.
Atropine eye drops are used to treat uveitis.
No uveitis indication is present in provided labeling excerpt.
Atropine eye drops are used to treat amblyopia (lazy eye).
The excerpt summary text given earlier by the user’s prompt claims amblyopia penalization is supported, but the provided label text included in this prompt excerpt only shows the indication header without the actual specific conditions; therefore this specific claim cannot be verified from the excerpt shown.
This reduction in secretions is sometimes utilized before surgery.
No perioperative/surgery use is present in provided labeling excerpt.
Common side effects of atropine include dry mouth.
Dryness of mouth is included as a systemic adverse event in the provided excerpt, but the excerpt lists it as part of systemic adverse events rather than explicitly as a “common side effect.” (Not enough to confirm “common.”)
Common side effects of atropine include blurred vision.
Blurred vision is included as a commonly occurring ocular adverse reaction, but the statement is phrased generally for atropine; label excerpt is specific to atropine sulfate ophthalmic solution and describes ocular reactions. Not fully verifiable as “common side effects” without frequency wording consistency.
Common side effects of atropine include sensitivity to light.
Photophobia is included, but the statement is phrased generally as a common side effect; frequency alignment cannot be confirmed from excerpt wording.
Common side effects of atropine include constipation.
Constipation is not mentioned in provided adverse reactions excerpt.
Common side effects of atropine include difficulty urinating.
Difficulty urinating/urinary retention is not mentioned in provided adverse reactions excerpt.
More serious side effects of atropine can include hallucinations.
Delirium is mentioned, but hallucinations are not explicitly listed in the provided excerpt.
More serious side effects of atropine can include dizziness.
Dizziness is not mentioned in provided excerpt.
More serious side effects of atropine can include heat prostration, especially in hot environments.
Heat prostration is not mentioned in provided excerpt.
Atropine is a naturally occurring alkaloid found in plants like Atropa belladonna (deadly nightshade).
Not addressed in provided label excerpt.
Specific formulations, delivery methods, or new uses of atropine may be subject to patenting.
Not a prescribing information claim; not addressed in provided excerpt.
For systemic effects, atropine can be given intravenously.
Provided label excerpt is for topical ophthalmic instillation; other routes are not supported.
For systemic effects, atropine can be given intramuscularly.
Provided label excerpt is for topical ophthalmic instillation; other routes are not supported.
For systemic effects, atropine can be given subcutaneously.
Provided label excerpt is for topical ophthalmic instillation; other routes are not supported.
Atropine can be inhaled as a mist for respiratory conditions.
No inhalation formulation/route is described in provided label excerpt.
Other medications like epinephrine or dopamine may be used as alternatives or in conjunction with atropine for bradycardia.
No bradycardia indication/therapy context is present in the provided labeling excerpt.
In ophthalmology, other mydriatic and cycloplegic agents such as cyclopentolate may have shorter durations of action than atropine.
No comparative duration claims involving other agents are included in the provided label excerpt.
In ophthalmology, other mydriatic and cycloplegic agents such as tropicamide may have shorter durations of action than atropine.
No comparative duration claims involving other agents are included in the provided label excerpt.
Other anticholinergic agents can be used for organophosphate poisoning.
Organophosphate poisoning context is not present in provided label excerpt.
Pralidoxime is often administered alongside atropine for organophosphate poisoning to reactivate inhibited enzymes.
Organophosphate poisoning context is not present in provided label excerpt.
Atropine can reduce secretions from the stomach.
Systemic adverse events mention dryness of mouth and throat; stomach-specific secretions are not mentioned.
Atropine can reduce secretions from the lungs.
Respiratory/lung-specific secretion effects are not mentioned in provided excerpt.
Blocking muscarinic acetylcholine receptors relaxes smooth muscles in the gastrointestinal and urinary tracts.
Not addressed in provided label excerpt.
Atropine anticholinergic side effects can be particularly problematic for elderly patients.
No elderly-specific warning is included in provided excerpt.
Atropine can cause confusion in older patients.
Delirium/confusion is mentioned as a systemic CNS effect, but not specified as “older patients.”
Atropine can exacerbate glaucoma.
Not mentioned in provided excerpt.
Atropine can exacerbate prostatic hypertrophy.
Not mentioned in provided excerpt.
Overdose of atropine can lead to severe anticholinergic toxicity.
Overdose/toxicity is not addressed in the provided label excerpt.
Severe anticholinergic toxicity from atropine overdose can manifest as high fever.
Not addressed in provided label excerpt.
Severe anticholinergic toxicity from atropine overdose can manifest as rapid heart rate.
Not addressed as overdose-specific; tachycardia is mentioned as a systemic adverse event, but not as an overdose manifestation.
Severe anticholinergic toxicity from atropine overdose can manifest as central nervous system excitation or depression.
No overdose/anticholinergic toxicity section provided in excerpt.
Contradictions
Important Omissions
No mention of labeled dosing instructions for atropine sulfate ophthalmic solution 1% (e.g., 1 drop to the conjunctival cul-de-sac 40 minutes prior to maximal dilation; repeat up to twice daily in adults and pediatric patients aged 3 years and older; pediatric 3 months to 3 years limit).
Importance:
Moderate
No mention of labeled contraindication: hypersensitivity to any ingredient.
Importance:
Moderate
No mention of labeled warnings such as duration of photophobia/blurred vision up to 2 weeks and elevation of blood pressure from systemic absorption, plus administration hygiene (do not touch dropper tip).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple statements are unsupported relative to the provided atropine sulfate ophthalmic solution 1% labeling excerpt, including non-ophthalmic indications, systemic administration routes, and organophosphate/bradycardia use. Several safety statements (e.g., glaucoma/prostatic hypertrophy/overdose manifestations) are not supported by the provided label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many claims are outside the scope of atropine sulfate ophthalmic solution 1% label excerpt (indications, administration routes, organophosphate/bradycardia therapy, overdose manifestations, and other ophthalmic comparisons).
Suggested Improvement
Limit claims to what is explicitly supported in the atropine sulfate ophthalmic solution 1% prescribing information excerpt: labeled indications, ocular administration timing/dosing, labeled contraindications, and labeled adverse reactions/warnings (photophobia/blurred vision duration, possible BP elevation, and contamination prevention). Avoid unsupported systemic/poisoning/bradycardia route and overdose-specific assertions.